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Abstract In this review, we explore the concept of ‘double
diabetes’, a combination of type 1 diabetes with features of
insulin resistance and type 2 diabetes. After considering
whether double diabetes is a useful concept, we discuss
potential mechanisms of increased insulin resistance in type
1 diabetes before examining the extent to which double
diabetes might increase the risk of cardiovascular disease
(CVD). We then go on to consider the proposal that weight
gain from intensive insulin regimens may be associated with
increased CV risk factors in some patients with type 1
diabetes, and explore the complex relationships between
weight gain, insulin resistance, glycaemic control and CV
outcome. Important comparisons and contrasts between type
1 diabetes and type 2 diabetes are highlighted in terms of
hepatic fat, fat partitioning and lipid profile, and how these
may differ between type 1 diabetic patients with and without
double diabetes. In so doing, we hope this work will stim-
ulate much-needed research in this area and an improvement
in clinical practice.
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CAC Coronary artery calcification
CVD Cardiovascular disease
EDC Epidemiology of Diabetes Complications
EDIC Epidemiology of Diabetes Interventions and
Complications
eGDR Estimated glucose disposal rate
EHI Estimated hepatic insulin
FAS Fatty acid synthase
HDL-C HDL-cholesterol
HL Hepatic lipase
IDF International Diabetes Federation
LPL Lipoprotein lipase
NCEP National Cholesterol Education Program
SREBP1c Sterol regulatory element-binding protein 1c
Introduction
In this review, we address the following questions: (1) What
are the potential mechanisms linking type 1 diabetes with
insulin resistance and how is this combination (‘double
diabetes’) associated with increased cardiovascular risk?
(2) Might weight gain associated with intensive insulin
regimens be associated with increased insulin resistance
and what implications might this have for cardiovascular
risk? (3) What role does the liver play in double diabetes?
(4) Might we need to consider changes in current clinical
practice in the context of the issues raised in this review?
Double diabetes
The term ‘double diabetes’ was first coined in 1991 based
on the observation that patients with type 1 diabetes who
had a family history of type 2 diabetes were more likely to
be overweight and rarely achieved adequate glycaemic
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control even with higher insulin doses [1]. The more exten-
sive, or stronger, the family history, the higher the dose the
patient received. The authors suggested that this might in-
dicate the presence of increased resistance to insulin-
mediated glucose disposal in this subgroup of people with
type 1 diabetes and asserted that, over a lifetime, some of
these individuals would likely have been diagnosed with
type 2 diabetes at some point, had they not first developed
beta cell destruction by an independent pathological process
(i.e. type 1 diabetes). At this stage, it is important to differ-
entiate this description of double diabetes, which considers
autoimmune diabetes to be an independent process from
obesity and insulin resistance, from the accelerator hypoth-
esis [2], which describes triggering of autoimmune diabetes
by factors including BMI and insulin resistance.
Other studies of people with type 1 diabetes and a family
history of type 2 diabetes have supported the notion that this
combination might promote both microvascular and
macrovascular complications of type 1 diabetes. For example,
in a prospective study of 3250 patients with type 1 diabetes
recruited from 16 European countries (EURODIAB), it was
demonstrated that women with a parental history of type 2
diabetes had a higher risk of developing albuminuria than
those without a positive family history (HR 1.36, p=0.04)
[3]. Furthermore, in a cross-sectional study of 658 patients
from the Pittsburgh Epidemiology of Diabetes Complications
(EDC) cohort, 112 of whom had a confirmed family history of
type 2 diabetes, and 119 of whom had experienced a CHD
event, a positive family history was associated with a signif-
icant excess risk of CHD (HR 1.89, 95% CI 1.27, 2.84) [4].
Those with a greater number of affected familymembers had a
greater risk (p=0.001 for trend), with one family member
conferring an OR of 1.62 and two family members increasing
this to 5.13 [4]. These data are consistent with either geneti-
cally determined insulin resistance/double diabetes or shared
parental–offspring lifestyle factors contributing to type 2 dia-
betes in parents and increasing the risk of complications.
Given the results of genome-wide association studies of type
2 diabetes published to date [5], the latter explanation current-
ly appears more plausible.
Measuring insulin resistance in type 1 diabetes
and examining its association with complications
Clamp studies If insulin resistance, either inherited or ac-
quired, is implicated in the pathogenesis of double diabetes,
how is it likely to manifest and can it be identified? The gold
standard method of measuring insulin-mediated glucose
uptake is the hyperinsulinaemic–euglycaemic clamp tech-
nique. Although this is a time-consuming and relatively
invasive technique, several investigators have employed it
to demonstrate increased insulin resistance in those with
type 1 diabetes compared with age-, sex- and BMI-
matched controls [6–16].
In one such study of 40 cases (mean age 45 years, mean
diabetes duration of type 1 diabetes 23 years) and 47 age-
and sex-matched control individuals, patients with type 1
diabetes not only had lower whole body insulin-mediated
glucose uptake (mean ± SE: 6.19±0.72 vs 12.71±0.66 mg
[kg fat-free mass]−1min−1, p<0.0001) but also had lower
insulin-mediated NEFA suppression. Both measurements
were correlated (p<0.0001 within the type 1 diabetes group)
with coronary artery calcification (CAC) measured by com-
puted tomography. Of note, HbA1c did not correlate with
either insulin resistance or CAC [16].
Derived measures of insulin resistance Data from one
clamp study [6], (n=24) were used to derive estimated
glucose disposal rate (eGDR) from a ‘best-fit’ model:
eGDR ¼ 24:31 12:22 WHRð Þ  3:29 hypertension statusð Þ
 0:57 HbA1cð Þ
where hypertension status (1 or 0) is defined as BP >
140/90 mmHg or on anti-hypertensive drugs; HbA1c refers
to the value in %. Low eGDR was proposed as a surrogate
measure of insulin resistance for use either in a clinical
setting or for epidemiological analyses [6].
Prediction of CVD using eGDR
eGDR was tested prospectively in 603 type 1 diabetes
Pittsburgh EDC cohort participants (mean baseline age
28 years, mean diabetes duration 19 years) followed up over
10 years [17]. Independent predictors of CVD events (n=42)
were disease duration, presence of nephropathy, non-HDL-
cholesterol (HDL-C), white cell count and eGDR. HbA1c was
not in itself a predictor, except as a component of eGDR [17].
However, in a subsequent analysis of the same cohort by the
same group, eGDR did not appear in CHD risk prediction
models (although, importantly, these incorporated three of its
individual components: WHR, HDL-C and BP) [18].
In an independent examination of the DCCT/Epidemiology
of Diabetes Interventions and Complications (EDIC) data,
Kilpatrick et al estimated eGDR retrospectively (using BMI
data instead of WHR) as a predictor of CVD events. In a Cox
regression model, high eGDR as a surrogate for preserved
insulin sensitivity was independently associated with a lower
risk for CV events (HR 0.70; 95% CI 0.56, 0.88) [19]. In
contrast, total insulin dose requirement had no predictive val-
ue. Intriguingly, high eGDR was also associated with a lower
risk for microvascular events, including retinopathy and ne-
phropathy—a finding also corroborated by data from the
EURODIAB study [20].
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Other derived measures related to insulin resistance:
does the metabolic syndrome identify CVD risk in type 1
diabetes?
Given the mechanistic relevance of insulin resistance in the
metabolic syndrome, a number of prospective studies have
assessed the utility of various definitions of the metabolic
syndrome in predicting risk in type 1 diabetes cohorts.
However, as the glycaemia criterion of the WHO, National
Cholesterol Education Program (NCEP) and International
Diabetes Federation (IDF) definitions are automatically ful-
filled, there is a major caveat. For example, an individual
with type 1 diabetes can meet the WHO definition by virtue
of microalbuminuria alone, even if non-obese and with a
normal lipid profile.
In a prospective analysis of the Pittsburgh EDC cohort,
the prevalence of the metabolic syndrome was 21% (WHO
definition), 12% (NCEP) and 8% (IDF). Using a composite
endpoint of CHD, renal failure and diabetes-related death,
the metabolic syndrome conferred significantly elevated
HRs (NCEP: 5.8, 95% CI 3.9, 8.6; WHO: 6.5, 95% CI
4.5, 9.4); however, these ratios were not higher than those
for individual components of the syndrome (for example,
microalbuminuria: 6.3, 95% CI 3.8, 10.5; BP 4.5, 95% CI
3.1, 6.6; triacylglycerol: 4.4, 95% CI 3.0, 6.6) [21].
In a similar analysis of the FinnDiane study [22], a high
prevalence of the metabolic syndrome was reported (44%
WHO definition; 35% NCEP; 36% IDF). The WHO defini-
tion predicted incident CV events after adjustment for tradi-
tional risk factors and nephropathy (HR 2.05, 95% CI 1.38,
3.04), even in participants with raised albumin excretion
(HR 1.44, 95% CI 1.06, 1.96). However, the individual
components of the metabolic syndrome were also signifi-
cant predictors, with the exception of obesity. In the
DCCT/EDIC study, an adapted IDF definition of the meta-
bolic syndrome had a baseline prevalence of 22%, largely
driven by low HDL-C, but did not predict either macro- or
microvascular events over 17 years of follow-up [19].
Thus, in broad terms, the metabolic syndrome and its
individual features are associated with more events but, as in
the general population [23], dichotomous classification of
individuals with type 1 diabetes according to the metabolic
syndrome does not appear to add value for CV risk prediction
in type 1 diabetes over and above its individual components.
Intensive insulin therapy, weight/weight gain
and their relationship to insulin resistance and CV risk
in type 1 diabetes
It is generally accepted that intensive insulin therapy re-
duces the incidence of CVD in type 1 diabetes. The most
robust interventional clinical trial evidence for this is from
the DCCT in which 1,441 adolescents and young adults
(mean age 27 years, BMI 28 kg/m2) were randomised for
6.5 years to intensive or conventional glycaemic control and
followed up post-randomisation in the EDIC study up to a
total of 17 years [24]. Intensive glycaemic control was
associated with a 57% reduction in RR (95% CI 12, 79%,
p=0.02) in a composite endpoint of non-fatal MI, stroke or
CV death (approximate overall rate of six events per 1,000
patient-years) [24]. Of course, one of the consequences of
intensive therapy is weight gain; the intensively treated
group in the DCCT study gained 4.6 kg more than the
conventionally treated group over the 5 year study period
[25].
In this context, subgroup analyses of the DCCT/EDIC
study have raised concerns about participants in whom
weight gain over the course of the trial was associated with
the emergence of features associated with increased CV risk
(Table 1) [26]. Those in the highest quartile for weight gain
exhibited higher BP and LDL-cholesterol (LDL-C) values, a
higher insulin dose requirement and WHR and a more
atherogenic lipid profile (raised apolipoprotein B, high
VLDL, higher small, dense LDL, lower apolipoprotein A-I
and lower HDL). In the intensive group, mean BMI in-
creased from 24 to 31 kg/m2. These differences remained
significant after adjustment for HbA1c [26]. A similar pat-
tern was observed among those allocated to conventional
treatment (albeit with a reduced effect size) [26], which is
consistent with the existence of individual predisposing
factors to insulin-induced weight gain, an area that merits
further study.
Interestingly, in the DCCT/EDIC study, a family history
of type 2 diabetes was also a significant independent pre-
dictor of weight gain in both the conventional and intensive
groups [27], consistent with an inherited tendency to store
excess fat in response to insulin, a degree of inherited
peripheral insulin resistance and/or a familial effect on en-
vironmental factors (energy intake and physical activity).
There is increasing contemporary evidence that the prev-
alence of obesity has risen substantially among the type 1
diabetic population, as it has in the general population. For
example, in the Pittsburgh EDC cohort between 1987 and
2007 the prevalence of obesity rose sevenfold (to 22.7%)
and overweight increased by 47% (to 42%) [28]. While in
the pre-DCCT era baseline BMI in patients with type 1
diabetes was lower than population norms, probably owing
to a combination of weight loss prior to diagnosis and
suboptimal glycaemic control, current BMI patterns are
similar. Although much of the weight gain seen in contem-
porary patients with type 1 diabetes is likely to reflect
cultural, societal and lifestyle changes, some of this increase
may be due to use of more intensive insulin regimens.
Mechanisms for the latter may include reduced excretion
of urinary glucose and altered feeding behaviour (more
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frequent treatment of hypoglycaemic episodes, appetite
stimulation), in addition to the known anabolic effects of
insulin.
Adverse CV risk factors associated with weight gain
in some recipients of intensive insulin therapy were also
seen in the observational data from the EURODIAB
cohort, in which 1,800 type 1 diabetic patients (mean
age 33 years, duration of diabetes 14.8 years, HbA1c
8.2% [66 mmol/mol]) were followed up for 7.3 years
[29]. Those who gained more than 5 kg over this time
had better glycaemic control (mean HbA1c difference of
0.2%) than those with less or no weight gain but also
had raised BP, LDL-C and triacylglycerol in association
with lower HDL-C (differences that remained significant
after adjustment for glycaemic control).
Insulin resistance in type 1 diabetes might relate to
the route of administration of therapeutic exogenous
insulin. Insulin absorbed from subcutaneous depots re-
sults in relative peripheral hyperinsulinaemia and hepat-
ic hypoinsulinaemia compared with normal physiology.
Chronic adaptation to this combination could reduce
peripheral insulin-mediated glucose uptake and increase
hepatic glucose production. In addition, it has been
proposed that reduced hepatic insulin exposure results
in a reduced level of circulating IGF-1, which, along
with a parallel increase in growth hormone and IGF-
binding proteins, may also contribute to increased pe-
ripheral insulin resistance [30, 31].
Therefore, several factors could underlie the phenotype
of double diabetes (Fig. 1). First, the genetic and lifestyle
factors that lead to type 2 diabetes may exist at similar
frequency in those with type 1 diabetes—this would be
consistent with the robust data on family history of type 2
diabetes described above. Second, weight gain caused by
intensive insulin therapy may lead to insulin resistance.
Third, exogenous insulin therapy might induce insulin re-
sistance in patients with type 1 diabetes.
There are several important unanswered questions:
1. Are some people with type 1 diabetes (including those
with a family history of type 2 diabetes or of specific
ethnicities, e.g. South Asians) more susceptible to
weight gain during intensive insulin treatment, perhaps
owing to differences in metabolism or substrate han-
dling – or can the observations regarding weight gain
simply be explained by the fact that those who are more
insulin resistant are treated with higher doses of insulin?
2. What are the most important factors, e.g. inherited or
familial factors, differences in feeding strategies for
avoidance of hypoglycaemia, insulin resistance?
3. To what extent do adverse CVD risk factors associated
with higher weight gain attenuate or reverse the pre-
sumed earlier CV (and other) benefits of intensive
glycaemic control in type 1 diabetes?
Lipid metabolism in type 1 diabetes
Insulin not only exerts effects on peripheral glucose uptake
and suppression of hepatic glucose production, it also has
profound effects on fat partitioning by promoting hepatic
Table 1 Characteristics of the
intensively treated group at
follow-up
aBaseline BMI was 24 kg/m2
for all quartiles
Adapted from [26] with permis-
sion. Copyright © (1998)
American Medical Association.
All rights reserved
Quartiles of weight gain 1 2 3 4
HbA1c (%) [mmol/mol] 7.3 [56] 7.2 [55] 7.1 [54] 7.3 [56]
Insulin dose (units kg−1 day−1) 0.61 0.64 0.69 0.74
Achieved BMIa (kg/m2) 24 25 27 31
Systolic BP (mmHg) 113 117 115 120
Triacylglycerol (mmol/l) 0.79 0.82 0.91 0.99
LDL-cholesterol (mmol/l) 2.74 2.79 2.92 3.15
HDL-cholesterol (mmol/l) 1.40 1.34 1.29 1.27
T1DM-induced
insulin resistance
Acquired (lifestyle)
insulin resistance
Genetic/familial 
insulin resistance
Double diabetes
Fig. 1 Mechanisms potentially contributing to insulin resistance in
type 1 diabetes patients with double diabetes. T1DM, type 1 diabetes
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and peripheral lipogenesis (fat storage) as well as suppress-
ing hepatic and peripheral lipolysis (inhibition of fat oxida-
tion). In this section, we compare lipid handling in type 1
diabetes with non-diabetic metabolism and with type 2
diabetes.
The most obvious and striking difference between type
1 diabetes on the one hand and obesity/type 2 diabetes
on the other, is low portal vein insulin concentration.
This can be concluded by inference from the understand-
ing of type 1 diabetes pathophysiology and anatomy (i.e.
if beta cells are not secreting insulin, then portal insulin
levels will be low, only reflecting recirculating insulin
from subcutaneous injection). Further evidence for this is
reviewed below and includes extrapolation from animal
models. In type 1 diabetes, absent pancreatic insulin
secretion is the opposite phenotype to the endogenous
hyperinsulinaemia characteristic of most conditions
characterised by insulin resistance. As type 1 diabetes is
characterised by higher peripheral insulin concentrations
and lower portal concentrations, it follows that contrast-
ing hepatic and peripheral lipid handling might be
predicted.
Reduced hepatic fat In contrast to obesity and type 2 dia-
betes, in which the importance of non-alcoholic
steatohepatitis (fatty liver) has been highlighted [32],
there is some evidence that intra-hepatic fat content is
reduced in type 1 diabetes. Comparing 19 patients with
type 1 diabetes (mean age 35, BMI 23 kg/m2, HbA1c
8.7% [72 mmol/mol]) and carefully matched non-
diabetic controls using 1H magnetic resonance spectros-
copy, Perseghin et al demonstrated significantly reduced
intra-hepatic fat content in those with type 1 diabetes
(1.5±0.7% vs 2.2±1.0%, p<0.03) [9]. This was associ-
ated with increased fasting lipid oxidation (1.5±0.7 vs
0.8±0.4 mg/kg). The estimated hepatic insulin (EHI)
level was lower and the glucagon:EHI ratio (reported
as an indicator of the balance between catabolism and
anabolism) was higher in the type 1 diabetes group
(both p<0.05) [9].
Hyperinsulinaemia has been shown to promote the depo-
sition of hepatic fat. Insulin stimulates sterol regulatory
element-binding protein 1c (SREBP1c), which plays a cru-
cial role in the regulation of triacylglycerol accumulation in
the liver [32–35]. Moreover, two enzymes involved in de
novo lipogenesis, namely, fatty acid synthase (FAS) and
acetyl-CoA carboxylase, are activated by SREBP1c. In par-
allel with this, hepatic fatty acid oxidation is inhibited and
the balance shifts to lipid storage as triacylglycerol is
incorporated into VLDL [33, 36]. It has been suggested that
relative under-insulinisation of the liver with preserved glu-
cagon secretion in type 1 diabetes favours a shift in metab-
olism from lipid storage to oxidation [9].
Fat partitioning Fat partitioning (the tissue distribution of
fat storage) reflects the balance of lipogenesis and fat oxi-
dation in different tissues. In type 1 diabetes, this is likely to
be influenced by the absence of endogenous insulin com-
bined with therapeutic administration of subcutaneous insu-
lin into the peripheral (as opposed to portal) circulation.
This results in reduced inhibition of hepatic lipolysis with
consequent increased levels of circulating NEFAs, which, in
combination with peripheral hyperinsulinaemia, may pro-
mote relatively greater lipid storage in skeletal muscle [7–9].
This is supported by recent evidence from recipients of
hepatic islet cell transplants, in whom OGTT-induced
NEFA suppresion was normalised [37]. The subsequent
pattern of increased (ectopic) intramyocellular fat storage
is similar to that found in obesity/type 2 diabetes and is
associated with impaired sensitivity of muscle to glucose
uptake, i.e. peripheral insulin resistance [38]. Therefore, in
type 1 diabetes, this may represent an indirect mechanism of
insulin resistance. Taking this idea further, anything that
exaggerates these features (i.e. increased fat mass, increased
lipid/NEFA flux, higher insulin dose requirements) is likely
to promote further insulin resistance.
It follows that other sites of ectopic fat deposition might
be influenced by abnormal fat partitioning. For example,
epicardial and perivascular fat may play a role in modulating
coronary function and pathophysiology, providing a poten-
tial mechanism to link double diabetes with CVD. In this
regard, data have recently been published on epicardial fat
thickness (measured by echocardiography) in 36 type 1
diabetic patients and 43 matched controls. Not only was
epicardial fat thicker in those with type 1 diabetes (p<
0.0001), but it also correlated significantly with both WHR
(r=0.67, p=0.003) and eGDR (r=−0.55, p=0.0004) within
the patient group [39].
HDL-C HDL-C levels are normal or high in type 1 diabetes
unless renal impairment develops, in which case HDL-C
falls [7, 40–43]. Moreover, long-term survivors of type
1 diabetes are characterised by unusually high HDL-C
levels (1.84 mmol/l) [44], and patients with CHD events
have been shown to have lower HDL-C levels (along
with higher triacylglycerol and LDL-C levels) [45].
Exogenous insulin treatment usually drives higher mean
HDL-C levels in type 1 diabetes, but even those
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individuals with poorer glycaemic control have higher
levels than healthy controls [43]. Several mechanisms
have been suggested to explain this phenomenon. The
most important of these appears to be lipoprotein lipase
(LPL), which is highly active in adipocytes and avidly
hydrolyses triacylglycerol-rich particles, resulting in high
HDL-C levels. Peripheral hyperinsulinaemia associated
with strict glycaemic control is associated with increased
LPL activity and HDL-C, while poor glycaemic control
results in lower LPL activity and HDL-C [46, 47].
There may also be a smaller contribution from a reduc-
tion in the activity of hepatic lipase (HL), an enzyme
that hydrolyses triacylglycerol and phospholipids present
in circulating plasma lipoproteins. Low levels of portal
vein insulin in type 1 diabetes are associated with
reduced HL activity and increased HDL-C [48–50].
Increasing hepatic insulin exposure by changing insulin
delivery from the subcutaneous to the intraperitoneal
route reverses this pattern [50]. In contrast, in type 2
diabetes, raised HL activity secondary to portal
hyperinsulinaemia may contribute to low HDL-C levels.
Finally, phospholipid transfer protein activity is marked-
ly elevated in patients with type 1 diabetes, and this
activity is correlated with HDL-C levels [42].
High HDL-C levels in patients with type 1 diabetes are
likely to be atheroprotective, even though some composi-
tional abnormalities may reduce the protective effect.
However, if central obesity and insulin resistance then de-
velop (double diabetes), a more atherogenic lipid profile
seems to emerge. This assertion is supported by data from
a subgroup of 61 DCCT participants, in whom increased HL
activity accounted for most of the association between in-
creased intra-abdominal fat stores and decreased HDL-C
levels [49].
Portal insulinopenia and lipid effects As discussed above,
the liver is under-insulinised in type 1 diabetes. This
raises the hypothesis that type 1 diabetes may actually
confer simultaneous protective and harmful CV effects.
This is a difficult phenomenon to study, but interesting
insights have been gained from the field of pancreas
transplantation in type 1 diabetes. When an insulin-
secreting graft is attached to the portal vein, an appar-
ently more atherogenic lipid profile is later observed
than when it is attached to a systemic vein [51]. By
contrast, this model has also been used to demonstrate
that hepatic IGF-1 secretion is increased and growth
hormone secretion is reduced by increased portal insulin
levels, with the resultant systemic effects on insulin
resistance mentioned above [52]. A number of other studies
of patients on peritoneal dialysis (i.e. receiving insulin by
the portal vein route) support these findings. In all cases,
despite a more physiological method of delivering insulin,
the lipid profile switched to an apparently more atherogenic
pattern, with significant reductions in HDL-C and increases
in LDL-C:HDL-C ratios [50, 53–55]. The pathophysiolog-
ical significance of this is uncertain given Mendelian
randomisation studies showing that differences in HDL-C
levels do not necessarily result in harm or benefit [56].
Rather, HDL particle flux may be more important—again,
a difficult process to measure. Whatever the net effect of
portal insulinisation, it is of interest that new insulins have
been specifically developed to have a relatively more he-
patic than systemic mode of action; thus, we will shortly
have new tools to help answer the specific questions raised
by this review. We hypothesise that these insulins will help
avoid excess weight gain, peripheral insulin resistance and
cardiac fat accumulation, but may lead to greater liver fat.
The net effects of these insulins on CV outcomes will
therefore be of major interest.
Summary and conclusions
A summary of our current knowledge of double diabe-
tes and areas for future research is presented in the text
box. While the risks of CVD in type 1 diabetes may be
falling, the relative risk of CVD, CHD, stroke and all-
cause mortality continues to be unacceptably high for
this patient population [57]. Our current understanding
of double diabetes is insufficient to produce a rigid
definition, but the literature we have summarised sug-
gests that it has emerged as a relevant clinical concept
in which there is: (1) marked weight gain over time;
(2) a high daily insulin requirement; (3) a positive
family history of type 2 diabetes, particularly when
two or more relatives are affected; and/ or (4) a low
eGDR. Affected individuals may have high normal BP
(or hypertension) and relatively low HDL-C. Whether
these effects associated with greater weight gain in at-
risk individuals with double diabetes attenuate or re-
verse the vascular benefits of glycaemia reduction over
time, remains to be fully established. In the meantime,
avoidance of greater weight gain (while retaining
glycaemic benefits) would have quality of life benefits
for patients.
When a patient with type 1 diabetes on an intensive
insulin regimen is clearly gaining a significant amount of
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weight, early consideration should be given to adjusting that
regimen in the context of diet and lifestyle in an effort to
limit weight gain. It may also be useful to ascertain a more
complete family history of type 2 diabetes in such patients.
We suggest that the roles of structured educational ap-
proaches, continuous subcutaneous insulin infusion and
closed-loop systems are potentially useful future strategies
that should be assessed for the prevention and treatment of
double diabetes. Lower thresholds (BP and lipid lowering)
for primary prevention of CVD should also be explored, as
should the role of metformin as an ‘insulin-sparing’ agent
[58] (now being evaluated in the Reducing with Metformin
Vascular Adverse Lesions in Type 1 Diabetes [REMOVAL]
trial [59]). Furthermore, it needs to be determined, whether
newer insulins (currently in early trials) that target the liver
more than the systemic tissues can lessen weight gain and,
as a result, improve outcome in such patients.
From a basic science perspective, further elucidation of
the complex interplay of glucose and lipid factors driving
CV risk in type 1 diabetes could help to better identify at-
risk patients and improve primary prevention strategies.
Duality of interest The authors declare that there is no duality of
interest associated with this manuscript.
Summary of what is known and what remains unknown (and thus requires further research) in ‘double diabetes’
Known Unknown: areas for future research
Individuals with T1DM and positive FHT2 have
increased risks of albuminuria and CHD [3, 4].
Is the effect of FHT2 on complications in T1DM
mediated by genetic or familial factors (or both)?
Peripheral insulin resistance is a consistent feature of
T1DM (across the BMI range) [6–16].
Is peripheral insulin resistance in T1DM related to in-
creased ectopic fat stores (e.g. skeletal muscle) as a result
of abnormal fat partitioning owing to non-physiological
subcutaneous insulin administration?
Clamp and derived measures of insulin resistance in
T1DM predict coronary disease [16, 17, 19].
There are no prospective studies of baseline clamp insulin
resistance in a T1DM cohort with follow-up for incident
CV events.
Defining metabolic syndrome in T1DM does not add
value for CV risk prediction [19, 21, 22].
Newer risk models in contemporary populations of
T1DM patients are urgently needed.
DCCT participants in the intensive insulin therapy group
in the highest quartile for weight gain developed a higher
BP and a more atherogenic lipid profile [26].
Numbers of CV events in the DCCT/EDIC study are too
small to demonstrate any excess risk in those patients
who gained the most weight. Further prospective cohort
studies are required. It remains possible (and clinically
relevant) that a beneficial CV effect of intensive
glycaemic control might, in some patients, be outweighed
by the adverse effects of weight gain.
Hepatic fat stores are reduced while intramuscular and
epicardial fat stores are increased in lean patients with
T1DM compared with matched non-diabetic controls
[9, 39].
What is the effect of weight gain on hepatic fat stores (and
ectopic fat stores) in T1DM? Any increase in perivascular
or epicardial fat could have implications for CV risk.
In T1DM following pancreas transplant, portal vein
drainage results in a more atherogenic lipid profile than
systemic vein drainage [51]. Similar patterns are found in
patients on peritoneal dialysis (portal insulin delivery)
[53–55].
Do newer insulins that target liver rather than systemic
tissues lead to more liver fat but less weight gain overall
and less cardiac and intramyocellular fat accumulation?
How do newer vs current insulins affect the function of
HDL particles?
FHT2, family history of type 2 diabetes; T1DM, type 1 diabetes
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